Vical Incorporated (NASDAQ:VICL) to Present at Needham & Company Biotechnology and Medical Technology Conference June 12

Vical Incorporated (NASDAQ:VICL) will speak at the Needham & Company Biotechnology and Medical Technology Conference on Thursday, June 12 at 10:00 am ET.  A live webcast of the conference will be made available on the events page of the company’s website at vical.com.

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

The Company has three active independent development programs in the areas of infectious disease and cancer. These are a Phase III clinical trial using its Allovectin-7 immunotherapeutic in patients with metastatic melanoma; a Phase II clinical trial using its cytomegalovirus (CMV) DNA vaccine in hematopoietic cell transplant patients, and a Phase I clinical trial using its pandemic influenza DNA vaccine formulated with its Vaxfectin adjuvant.

The Company has licensing and collaboration arrangements, such as its licensing arrangements with Merck & Co., Inc. (Merck), the sanofi-aventis Group (sanofi-aventis), Aqua Health Ltd. of Canada, an affiliate of Novartis Animal Health, Merial Limited, a joint venture of Merck and sanofi-aventis and AnGes, among other research-driven biopharmaceutical companies.

Find more Conference Calls or post your own events on YourFindit Events.